Abacavir Sulfate is a pharmaceutical salt formed by ionic pairing of the active pharmacophore with a carefully selected counter-ion to optimise aqueous solubility, crystallinity, dissolution rate, and solid-state stability relative to the parent free form. Salt selection is a pivotal pharmaceutical development decision influencing polymorphic landscape, hygroscopicity, powder flow, compressibility, and bioavailability. Characterisation of Abacavir Sulfate by XRPD, DSC, TGA, and dynamic vapour sorption is essential to define the approved solid-state form and ensure consistent quality across manufacturing batches.
The Acceptable Daily Exposure (ADE) for Abacavir Sulfate is derived using methodology consistent with the ISPE Risk-Based Manufacture guide, providing an internally consistent health-based limit applicable across the complete pharmaceutical product lifecycle from API synthesis through to patient administration.
